Zai Lab
zailaboratory.com
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Zai Lab: Zoci Advances From IND To Global Phase 3 In Under Two Years As U.S. Submission Targets 2027
Zai Lab is rapidly advancing its internally developed oncology pipeline, with zocilurtatug pelitecan, or zoci, progressing from an Investigational New Drug application to global Phase 3 development in under two years.
Read more
Report
Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
Read more
Report
UBS Gives Zai Lab (ZLAB) a Buy Rating
Zai Lab Limited (NASDAQ:ZLAB) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On January 6, UBS initiated coverage on Zai Lab Limited (NASDAQ:ZLAB), giving the stock a Buy rating and setting the price target at $35. The re
Read more
Report
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors
SHANGHAI & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Jan. 6, 2026-Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO (repotre
Read more
Report
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Jan. 5, 2026-Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Janu
Read more
Report
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
COBENFY is the first major advance in schizophrenia treatment in decades, offering a novel mechanism of action distinct from other therapiesCOBENFY has already been included in China's national-level schizophrenia treatment guidelines, underscoring the ur
Read more
Report
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod
Read more
Report
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab's growing global pipeline ZL-1503 originated from Zai Lab's in-house discovery and development engine SHANGHA
Read more
Report
Zai Lab Announces Updates to China's National Reimbursement Drug List
SHANGHAI & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dec. 7, 2025-Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the following medicines and indications have been renewed in the 2025 National Reimbursement Drug List (NRDL) released by China's Nati
Read more
Report
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria in primary membranous nephropathy, and stabilization of estimated glomerular filtration rate across both diseases - Vertex on tra
Read more
Report
Show more news